Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Osteoclasts in Bone Remodeling01:31

Osteoclasts in Bone Remodeling

Osteoclasts are cells responsible for bone resorption and remodeling. They originate from hematopoietic progenitor cells present in the bone marrow. Numerous progenitor cells fuse to form multinucleated cells, each with 10-20 nuclei. A single osteoclast has a diameter of 150 to 200 µM. These cells have ruffled borders that break down the underlying bone tissue and release minerals such as calcium into the blood in bone resorption. Osteoclasts cling to bones with their ruffled edges during bone...
Bone Disorders01:29

Bone Disorders

Aging and its effect on bone remodeling is the most common cause of bone disorders. In young and healthy people, bone deposition and resorption happen at an equal rate to maintain optimal bone health.
Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...
Bone Remodeling01:40

Bone Remodeling

Bone remodeling is a continuous and balanced process of bone resorption by osteoclasts and bone formation by osteoblasts. In adults, it helps maintain bone mass and calcium homeostasis. While mechanical stress can stimulate turnover as part of the normal maintenance and reparative process, several hormones also regulate bone remodeling.
Bone Remodeling and Repair01:31

Bone Remodeling and Repair

Osteoclasts are cells responsible for bone resorption and remodeling. They originate from hematopoietic progenitor cells present in the bone marrow. Numerous progenitor cells fuse to form multinucleated cells, each with 10-20 nuclei. A single osteoclast has a diameter of 150 to 200 µM. These cells have ruffled borders that break down the underlying bone tissue and release minerals such as calcium into the blood in bone resorption. Osteoclasts cling to bones with their ruffled edges during bone...
What is the Skeletal System?01:02

What is the Skeletal System?

Overview
Chronic Kidney Disease II: Clinical Manifestations01:24

Chronic Kidney Disease II: Clinical Manifestations

Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Familial complete pachydermoperiostosis presenting with vertebral hypertrophy and myelopathy.

JBMR plus·2025
Same author

Kidney function, bone health, and vascular calcifications in patients with CKD II - IV: A 2 - 3 year prospective study with bone biopsies.

Clinical nephrology·2025
Same author

Celebrating 50-years: the history and future of the International Society of Bone Morphometry.

JBMR plus·2024
Same author

FGF-23 and sclerostin in serum and bone of CKD patients.

Clinical nephrology·2023
Same author

Treatment of bone loss in CKD5D: Better survival in patients with non-high bone turnover.

Clinical nephrology·2022
Same author

Trabecular bone microcrack accumulation in patients treated with bisphosphonates for durations up to 16 years.

Journal of orthopaedic research : official publication of the Orthopaedic Research Society·2022

Related Experiment Video

Updated: May 26, 2026

Practical Considerations for the Design, Execution, and Interpretation of Studies Involving Whole-Bone Bending Tests of Rodent Bones
04:20

Practical Considerations for the Design, Execution, and Interpretation of Studies Involving Whole-Bone Bending Tests of Rodent Bones

Published on: September 1, 2023

Differences in bone quality in low- and high-turnover renal osteodystrophy.

Hartmut H Malluche1, Daniel S Porter, Marie-Claude Monier-Faugere

  • 1Division of Nephrology, Bone and Mineral Metabolism, University of Kentucky, Albert B. Chandler Medical Center, Lexington, KY 40536-0298, USA. hhmall@uky.edu

Journal of the American Society of Nephrology : JASN
|December 24, 2011
PubMed
Summary

Bone quality in chronic kidney disease (CKD) is affected differently by low or high bone turnover. Low turnover impairs microstructure, while high turnover damages material and nanomechanical properties, impacting bone strength.

More Related Videos

Trabecular Bone Microarchitecture Evaluation in an Osteoporosis Mouse Model
06:59

Trabecular Bone Microarchitecture Evaluation in an Osteoporosis Mouse Model

Published on: September 8, 2023

Standardized Histomorphometric Evaluation of Osteoarthritis in a Surgical Mouse Model
07:32

Standardized Histomorphometric Evaluation of Osteoarthritis in a Surgical Mouse Model

Published on: May 6, 2020

Related Experiment Videos

Last Updated: May 26, 2026

Practical Considerations for the Design, Execution, and Interpretation of Studies Involving Whole-Bone Bending Tests of Rodent Bones
04:20

Practical Considerations for the Design, Execution, and Interpretation of Studies Involving Whole-Bone Bending Tests of Rodent Bones

Published on: September 1, 2023

Trabecular Bone Microarchitecture Evaluation in an Osteoporosis Mouse Model
06:59

Trabecular Bone Microarchitecture Evaluation in an Osteoporosis Mouse Model

Published on: September 8, 2023

Standardized Histomorphometric Evaluation of Osteoarthritis in a Surgical Mouse Model
07:32

Standardized Histomorphometric Evaluation of Osteoarthritis in a Surgical Mouse Model

Published on: May 6, 2020

Area of Science:

  • Nephrology
  • Orthopedics
  • Biomaterials Science

Background:

  • Abnormal bone turnover is prevalent in chronic kidney disease (CKD).
  • The specific effects of low or high bone turnover on bone quality in CKD patients are not fully understood.
  • Bone quality is crucial for mechanical competence and fracture prevention.

Purpose of the Study:

  • To investigate the distinct impacts of low and high bone turnover on bone quality in patients with CKD.
  • To compare bone microstructural, material, and nanomechanical properties across different turnover states.
  • To elucidate the mechanisms by which altered bone turnover affects bone health in CKD.

Main Methods:

  • Qualitative screening of iliac crest bone specimens from CKD patients on dialysis (low/high turnover) and healthy controls.
  • Quantitative analysis using Fourier transform infrared spectroscopy and nanoindentation for material and mechanical properties.
  • Bone histomorphometry to assess microstructural parameters, bone formation, and resorption.

Main Results:

  • Low turnover bone exhibited microstructural deficits, including reduced cancellous bone volume and trabecular thickness.
  • High turnover bone displayed material and nanomechanical abnormalities, such as decreased mineral to matrix ratio and lower stiffness.
  • Both low and high turnover states in CKD lead to diminished bone quality, but through distinct pathological pathways.

Conclusions:

  • Turnover-related alterations in bone quality significantly contribute to the reduced mechanical competence of bone in CKD.
  • Low and high bone turnover in CKD affect bone quality via different mechanisms, impacting microstructure and material properties, respectively.
  • Developing targeted therapies for low- or high-turnover renal osteodystrophy may improve treatment efficacy.